Scienza e Tecnologia
VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model
This milestone follows VelaVigo's first licensing deal with Avenzo Therapeutics in November 2024 and the successful close of a $50 million Pre-A funding round in February 2025 , reinforcing the company's unique business model combining business development (BD) and venture capital (VC) strategies for sustainable growth.
The latest deal underscores VelaVigo's ability to discover and develop high-potential therapeutics while partnering strategically to maximize value. Additionally, VelaVigo is advancing its fully owned lead asset, a FIC/BIC bispecific ADC, into a U.S. clinical trial this year and expanding its global clinical development capabilities. The company will also present data on five additional FIC or BIC molecules at upcoming industry conferences, seeking further partnership opportunities worldwide.
said Jing Li , CEO of VelaVigo.
said Tong Zhang, co-founder, Chief Business & Financial Officer of VelaVigo.
VelaVigo is a leading antibody/ADC discovery and development biotech company with a highly efficient discovery engine and strong capabilities in translational medicine, CMC and early clinical development. Its leading products, the FIC bispecific ADCs, are expected to enter clinical development in the US and China in 2025. VelaVigo continues to build capabilities in clinical development, technology platforms, and partnership with biopharmaceutical companies and investors globally to maximize the efficiency of drug development and return on investment.
VelaVigo was founded in 2021 with a $50M investment, its R&D centers in Shanghai , and clinical and US operations in Boston .
View original content:https://www.prnewswire.co.uk/news-releases/velavigo-announces-second-out-licensing-deal-of-a-first-in-class-bi-specific-antibody-further-validating-its-innovative-discovery-platform-and-sustainable-bdvc-business-model-302431724.html